AAV8-shTinagl1 had no effect on the mouse body weight (Figure 8C) but significantly decreased the degree of liver fibrosis (Figure 8D), liver / body weight ratio (Figure 8E), liver hydroxyproline content (Figure 8F), serum ALT and AST levels (Figure 8G), and also decreased fibrotic factors, proinflammatory cytokines, and PDGFRβ at mRNA and protein levels (Figure 8H) compared to the CCl4-injected group. Here, PDGFRB is linked to Hepatic fibrosis.